• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    AI Platforms, Data Infrastructure, and Healthcare Innovation Shape the Market Narrative

    3/11/26 10:00:26 AM ET
    $CYN
    $DOMO
    $KALA
    EDP Services
    Technology
    Computer Software: Prepackaged Software
    Technology
    Get the next $CYN alert in real time by email

    DENVER, March 11, 2026 (GLOBE NEWSWIRE) -- A fresh wave of developments across artificial intelligence, healthcare technology, and digital infrastructure is reinforcing a central theme dominating markets: the rapid convergence of AI with data-heavy industries. From biotech platforms deploying autonomous agents to data-center integrators scaling AI infrastructure, companies are positioning themselves to capture value from the next phase of the technology cycle.

    Leading the narrative is KALA BIO (NASDAQ:KALA), which announced it expects to deploy its first commercial AI agent within approximately two weeks as part of the rebranded Researgency.ai platform. The company is attempting to reposition itself from a traditional clinical-stage biotech into a hybrid model combining drug development with enterprise AI software.

    Kala's strategy centers on building specialized "agentic AI" tools for biotechnology and pharmaceutical companies, software agents designed to autonomously perform high-value operational tasks such as regulatory documentation, clinical trial protocol drafting, pharmacovigilance monitoring, and competitive intelligence analysis. The launch reflects the accelerating push toward AI automation across research-driven industries, where complex compliance requirements and massive scientific datasets create fertile ground for productivity gains.

    Another player seeking exposure to AI-driven healthcare infrastructure is Totaligent (OTCID: TGNT), which recently outlined plans to expand into the biologics ecosystem through strategic acquisitions. The company has signed letters of intent to acquire Aetherium Medical's platform and intellectual property and to form a joint venture with Japanese distributor GloMed Solutions, a business generating roughly $10 million in annual revenue and about $1 million in free cash flow.

    These moves aim to position Totaligent within the infrastructure layer supporting the rapidly expanding biologics market, a segment of medicine built around therapies derived from living cells that increasingly relies on AI-driven discovery and data analysis.

    While emerging companies pursue platform shifts, established enterprise software providers continue focusing on monetizing AI adoption. Domo (NASDAQ:DOMO) reported fiscal fourth-quarter revenue of $79.6 million, up 1% year over year, with subscription revenue reaching $73.4 million. More notably, billings climbed 8% to $111.2 million and the company recorded its highest quarterly billings to date.

    Domo's leadership emphasized growing demand as organizations move beyond AI experimentation and begin deploying production systems that automate workflows and operational decision-making. The company's improving non-GAAP operating margin, which rose to 10% in the quarter, underscores the ongoing shift toward profitability as AI analytics platforms mature.

    Automation is also gaining traction in industrial environments. Cyngn (NASDAQ:CYN) said it is on track to sell more autonomous vehicle solutions in the first quarter of 2026 than in all of 2025. The company's DriveMod Tugger platform, used to automate repetitive material transport inside manufacturing and logistics facilities, is seeing increasing adoption as customers move from pilot programs to full production deployments.

    The company noted that autonomous operating hours across its customer base surged more than 113% in the second half of last year, reflecting broader acceptance of AI-driven industrial automation.

    About 24/7 Market News

    In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company's profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact [email protected] to discuss how 24/7 can help accelerate your company's visibility and valuation trajectory.

    PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247 is a third-party media provider and has been compensated by one or more featured companies for providing ongoing TGNT market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please review 247's Full Disclaimer https://www.247marketnews.com/disclaimer/. Please go to https://go.247marketnews.com/tgnt-disclosure/ for further TGNT and 247marketnews.com disclosure information.

    CONTACT:

    24/7 Market News

    [email protected]

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.



    Get the next $CYN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CYN
    $DOMO
    $KALA

    CompanyDatePrice TargetRatingAnalyst
    Domo Inc.
    $DOMO
    2/13/2026$3.50Mkt Outperform → Mkt Underperform
    Citizens
    KALA BIO Inc.
    $KALA
    9/30/2025$1.50Outperform → Neutral
    Mizuho
    KALA BIO Inc.
    $KALA
    9/29/2025Buy → Neutral
    H.C. Wainwright
    KALA BIO Inc.
    $KALA
    9/29/2025Buy → Neutral
    Ladenburg Thalmann
    KALA BIO Inc.
    $KALA
    9/8/2025$30.00Outperform
    Mizuho
    Domo Inc.
    $DOMO
    8/26/2025$21.00Hold → Buy
    TD Cowen
    Domo Inc.
    $DOMO
    7/18/2025$19.00Overweight
    Stephens
    KALA BIO Inc.
    $KALA
    7/11/2025$12.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $CYN
    $DOMO
    $KALA
    SEC Filings

    View All

    Domo Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DOMO, INC. (0001505952) (Filer)

    3/10/26 4:17:37 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    SEC Form SCHEDULE 13D filed by Domo Inc.

    SCHEDULE 13D - DOMO, INC. (0001505952) (Subject)

    3/9/26 1:17:15 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by Domo Inc.

    SCHEDULE 13G/A - DOMO, INC. (0001505952) (Subject)

    3/6/26 10:30:41 AM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    $CYN
    $DOMO
    $KALA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Rpd Fund Management Llc claimed ownership of 4,613,726 units of Class B Common Stock (SEC Form 3)

    3 - DOMO, INC. (0001505952) (Issuer)

    3/9/26 1:20:40 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    SEC Form 3 filed by new insider Purdy Brendan P.

    3 - KALA BIO, Inc. (0001479419) (Issuer)

    2/9/26 4:16:24 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Berger Chaim D.

    3 - KALA BIO, Inc. (0001479419) (Issuer)

    2/9/26 4:15:14 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYN
    $DOMO
    $KALA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AI Platforms, Data Infrastructure, and Healthcare Innovation Shape the Market Narrative

    DENVER, March 11, 2026 (GLOBE NEWSWIRE) -- A fresh wave of developments across artificial intelligence, healthcare technology, and digital infrastructure is reinforcing a central theme dominating markets: the rapid convergence of AI with data-heavy industries. From biotech platforms deploying autonomous agents to data-center integrators scaling AI infrastructure, companies are positioning themselves to capture value from the next phase of the technology cycle. Leading the narrative is KALA BIO (NASDAQ:KALA), which announced it expects to deploy its first commercial AI agent within approximately two weeks as part of the rebranded Researgency.ai platform. The company is attempting to reposi

    3/11/26 10:00:26 AM ET
    $CYN
    $DOMO
    $KALA
    EDP Services
    Technology
    Computer Software: Prepackaged Software
    Biotechnology: Pharmaceutical Preparations

    With Sales Momentum Accelerating, Cyngn 'On Track' to Sell More in Q1 Than in All of 2025

    MOUNTAIN VIEW, Calif., March 11, 2026 /PRNewswire/ -- Cyngn (NASDAQ:CYN) today announced continued commercial momentum for its autonomous vehicle solutions, driven by expanding customer deployments, increased utilization across existing sites, and accelerating sales activity entering 2026. According to Marty Petratis, Cyngn's VP of Sales, the company is on track to sell more in Q1 of 2026 than all of last year based on current bookings and pipeline. Cyngn has seen a steady build in customer demand as enterprise manufacturers move from pilots into production deployments of its Dr

    3/11/26 7:00:00 AM ET
    $CYN
    EDP Services
    Technology

    Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates

    ARLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) announces that it is ready to ship its first commercial AI product in approximately 14 days, transforming the Company from a clinical-stage biotech into a dual-engine growth story powered by both a proprietary drug pipeline and a scalable AI platform targeting the $180+ billion AI-in-healthcare market. Kala is building the Palantir for biotech, just as Palantir built a $250+ billion company by helping governments and enterprises make sense of massive data, Kala is doing the same for the biotech and pharmaceutical industry through its Researgency.ai platform, deploying purpose-built AI agents that handle the r

    3/11/26 6:30:00 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYN
    $DOMO
    $KALA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Founder and CEO James Joshua G bought $165,897 worth of Class B Common Stock (13,025 units at $12.74), increasing direct ownership by 1% to 1,079,972 units (SEC Form 4)

    4 - DOMO, INC. (0001505952) (Issuer)

    6/23/25 9:37:55 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    Director Daniel Daniel David Iii bought $772,452 worth of Class B Common Stock (120,000 units at $6.44) (SEC Form 4)

    4 - DOMO, INC. (0001505952) (Issuer)

    4/4/25 9:37:24 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    Founder and CEO James Joshua G bought $502,172 worth of Class B Common Stock (77,300 units at $6.50) (SEC Form 4)

    4 - DOMO, INC. (0001505952) (Issuer)

    4/4/25 9:36:07 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    $CYN
    $DOMO
    $KALA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Domo downgraded by Citizens with a new price target

    Citizens downgraded Domo from Mkt Outperform to Mkt Underperform and set a new price target of $3.50

    2/13/26 8:28:18 AM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    KALA BIO downgraded by Mizuho with a new price target

    Mizuho downgraded KALA BIO from Outperform to Neutral and set a new price target of $1.50

    9/30/25 9:48:28 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KALA BIO downgraded by H.C. Wainwright

    H.C. Wainwright downgraded KALA BIO from Buy to Neutral

    9/29/25 1:25:35 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYN
    $DOMO
    $KALA
    Leadership Updates

    Live Leadership Updates

    View All

    Cyngn Adds Former Lyft Exec, Ran Makavy, to Board

    Mr. Makavy led growth at Lyft and later ran its core platform through the 2019 IPO. He also founded Snaptu, which was acquired by Facebook in 2011.MOUNTAIN VIEW, Calif., Feb. 25, 2026 /PRNewswire/ -- Cyngn (NASDAQ:CYN) today announced the appointment of Ran Makavy to its Board of Directors. He brings senior growth and platform leadership experience from Lyft and Facebook, where he helped scale large technology businesses through high-growth phases. At Lyft, Makavy built the growth team which was responsible for getting more drivers and riders to use Lyft and getting them to use

    2/25/26 7:05:00 AM ET
    $CYN
    EDP Services
    Technology

    Cyngn Partners with Chandler Automation, Expands into Agriculture

    MOUNTAIN VIEW, Calif., Dec. 23, 2025 /PRNewswire/ -- Cyngn (NASDAQ:CYN) today announced that Chandler Automation has joined its dealer network and will begin offering Cyngn's autonomous DriveMod Tugger to food processors and packers in the agriculture sector. Chandler Automation is a full-service partner in factory automation, specializing in optical sorting, inspection, robotic palletizing, and custom processing machinery. Known for delivering tailored, high-performance systems, Chandler empowers food processors to reduce labor costs, boost efficiency, and stay competitive wi

    12/23/25 7:00:00 AM ET
    $CYN
    EDP Services
    Technology

    KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director

    ARLINGTON, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Todd Bazemore has been named President and Chief Executive Officer (CEO) of KALA BIO and appointed to the Board of Directors. Mr. Bazemore has served as KALA's interim CEO since February 2025 and previously served as KALA's President and Chief Operating Officer (COO). "Throughout his tenure, including as interim CEO and President and COO, Todd's leadership has been instrumental in driving KALA's clinical progress and str

    9/2/25 8:00:00 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYN
    $DOMO
    $KALA
    Financials

    Live finance-specific insights

    View All

    Domo Announces Fourth Quarter and Fiscal 2026 Financial Results

    Domo, Inc. (NASDAQ:DOMO) today announced results for its fiscal fourth quarter and year ended January 31, 2026. Fiscal Fourth Quarter Results Total revenue was $79.6 million, an increase of 1% year over year Subscription revenue was $73.4 million, an increase of 2% year over year Billings were $111.2 million, an increase of 8% year over year Subscription Remaining Performance Obligations (RPO) was $437.9 million as of January 31, 2026, an increase of 8% year over year Current subscription RPO was $227.0 million as of January 31, 2026, an increase of 1% year over year GAAP operating margin was negative 13%, an improvement of 2 percentage points year over year Non-GAAP

    3/10/26 4:05:00 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    Cyngn Announces Date for 2025 Fourth Quarter and Year-End Financial Results

    MOUNTAIN VIEW, Calif., March 5, 2026 /PRNewswire/ -- Cyngn (NASDAQ:CYN) will announce its 2025 fourth quarter and year-end financial results for the period ended December 31, 2025, on Wednesday, March 25, 2026, after the close of market. The financial results will be available on the Cyngn website under "News & Events" at https://investors.cyngn.com/.  The Company will not host an earnings call.About CyngnCyngn develops and deploys autonomous vehicle technology for industrial organizations like manufacturers and logistics companies. The Company addresses significant challenges f

    3/5/26 7:05:00 AM ET
    $CYN
    EDP Services
    Technology

    Domo Announces Timing of its Fourth Quarter and Full-Year Fiscal 2026 Earnings Conference Call

    Domo (NASDAQ:DOMO) today announced that results for its fourth quarter and full-year fiscal 2026 (ended January 31, 2026) will be released on Tuesday, March 10, 2026, after market close. The company will host a conference call at 3:00 p.m. (MT) / 5:00 p.m. (ET) to discuss its financial results with the investment community. A live dial-in is available at (877) 484-6065 or (201) 689-8846. A live webcast of the event will also be available on the Domo Investor Relations website at www.domo.com/IR. A replay will be available at (877) 660-6853 or (201) 612-7415 with access ID# 13758775 following the completion of the conference call until 11:59 p.m. (ET) on April 10, 2026. About Domo Do

    2/27/26 9:00:00 AM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    $CYN
    $DOMO
    $KALA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by KALA BIO Inc.

    SC 13G - KALA BIO, Inc. (0001479419) (Subject)

    11/14/24 4:49:42 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Domo Inc.

    SC 13G/A - DOMO, INC. (0001505952) (Subject)

    11/14/24 12:25:56 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G filed by Domo Inc.

    SC 13G - DOMO, INC. (0001505952) (Subject)

    11/13/24 5:19:29 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology